Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  CanSino Biologics Inc.    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Number of employees : 429 people.
Sales per Business
20182019Delta
HKD (in Million)%HKD (in Million)%
Pharmaceutical1.34176.6%---
Sales per region
20182019Delta
HKD (in Million)%HKD (in Million)%
China1.34176.6%---
Managers
NameAgeSinceTitle
Xue Feng Yu562009Chairman, Chief Executive Officer & GM
Jiang Feng Li422019Chairman-Supervisory Board
Shou Bai Chao572018COO, Executive Director & Deputy General Manager
Jing Wang392017Chief Financial Officer & Board Secretary
Tao Zhu, Dr.462009Executive Director, CSO & Deputy General Manager
Jun Qiang Li--Senior Director-Research & Development
Dong Xu Qiu, Dr.592009Executive Director & Deputy General Manager
Qiang Xu512011Non-Executive Director
Liang Lin452013Non-Executive Director
Ying Yu Liang492015Non-Executive Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 132,670,900 98,072,500 73.9% 0 0.0% 37.1%
Stock B 0 114,778,999 0 0.0% 0 0.0%
Stock C 0 16,724,200 0 0.0% 0 0.0%
Shareholders
NameEquities%
Lilly Asia Ventures 20,585,562 15.5%
Qiming Venture Partners Ltd. 13,036,538 9.83%
Hui Hua Mao 11,924,700 8.99%
Xue Feng Yu 11,590,183 8.74%
Dong Xu Qiu 11,083,517 8.35%
Capital Research & Management Co. (World Investors) 10,887,004 8.21%
OrbiMed Advisors LLC 7,967,600 6.01%
HSBC Global Asset Management (Hong Kong) Ltd. 6,608,000 4.98%
Capital Research & Management Co. (Global Investors) 6,583,697 4.96%
The Vanguard Group, Inc. 2,574,748 1.94%
Company contact information
CanSino Biologics, Inc.
4/F, Room 401-420, Biomedical Park
No. 185 South Street
TEDA West District
Tianjin 300457

Phone : +86.22.58213766
Fax : +86.22.58213626
Web : http://www.cansinotech.com